BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20385991)

  • 1. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
    Lyman GH; Dale DC; Wolff DA; Culakova E; Poniewierski MS; Kuderer NM; Crawford J
    J Clin Oncol; 2010 Jun; 28(17):2914-24. PubMed ID: 20385991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
    Feng X; Lan H; Ruan Y; Li C
    Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
    Kuderer NM; Dale DC; Crawford J; Lyman GH
    J Clin Oncol; 2007 Jul; 25(21):3158-67. PubMed ID: 17634496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
    Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
    Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
    Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.
    Lyman GH; Dale DC; Culakova E; Poniewierski MS; Wolff DA; Kuderer NM; Huang M; Crawford J
    Ann Oncol; 2013 Oct; 24(10):2475-2484. PubMed ID: 23788754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
    Zhang JL; Cao YP; Li JG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):494-503. PubMed ID: 30998160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.
    Lyman GH; Yau L; Nakov R; Krendyukov A
    Ann Oncol; 2018 Sep; 29(9):1903-1910. PubMed ID: 30099478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.
    Gurion R; Belnik-Plitman Y; Gafter-Gvili A; Paul M; Vidal L; Ben-Bassat I; Shpilberg O; Raanani P
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008238. PubMed ID: 21901718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
    Smith RE; Bryant J; DeCillis A; Anderson S;
    J Clin Oncol; 2003 Apr; 21(7):1195-204. PubMed ID: 12663705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
    Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].
    Chen YX; Ma XR; Zhang WG; Liu J; Cao XM; He AL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1002-5. PubMed ID: 18928583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
    Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
    N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
    Bernell P; Kimby E; Hast R
    Leukemia; 1994 Oct; 8(10):1631-9. PubMed ID: 7934158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
    Ganser A; Heil G; Kolbe K; Maschmeyer G; Fischer JT; Bergmann L; Mitrou PS; Heit W; Heimpel H; Huber C
    Ann Hematol; 1993 Mar; 66(3):123-5. PubMed ID: 7682447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Risk of Clonal Evolution of Granulocyte Colony-Stimulating Factor for Acquired Aplastic Anemia: A Systematic Review and Meta-Analysis.
    Ding SX; Chen T; Wang T; Liu CY; Lu WL; Fu R
    Acta Haematol; 2018; 140(3):141-145. PubMed ID: 30253387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.